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WPE3
HEALTH ECONOMISTS AND MANAGED CARE 
DECISION-MAKERS: BRIDGING THE GAP
Bala MV1, Westrick E2, Mauskopf JA3
1Centocor, Inc., Malvern, PA, USA; 2MIM Health Plans, 
Providence, RI, USA; 3Research Triangle Institute, Research 
Triangle Park, NC, USA
WORKSHOP OBJECTIVE: The objective of this work-
shop is to demonstrate, using an interactive format, what
will make pharmacoeconomics more useful to managed
care decision-makers.
PARTICIPANTS WHO WOULD BENEFIT: Analysts or
decision-makers involved in the conduct or evaluation of
pharmacoeconomic studies.
Even though substantial investments are being made in
funding health economics studies, there is not much evi-
dence that the results of these studies are being effectively
used in decision-making within managed care organiza-
tions. In this workshop we examine potential reasons for
this disconnect between health economists and managed
care decision-makers by engaging in a discussion among
two health economists, a managed care decision-maker
and the workshop participants. The managed care deci-
sion-maker will describe the tools, such as formulary ex-
clusions, formulary restrictions with prior authorization
requirement, and treatment guidelines, that managed
care organizations use to enforce prescription of cost-
effective medications by their member physicians. He will
also describe what drug value information is used in de-
veloping these tools. The health economists will then
present potential modifications to standard pharmaco-
economic analyses that will allow managed care decision-
makers to integrate study results into these tools. They
will illustrate this using results of two new drug valuation
analyses, a cost-effectiveness analysis and a population
cost and outcome study. The managed care decision-
maker will then lead the workshop participants in a dis-
cussion about how each of these analyses could be useful
for making decisions about the new drugs. The discus-
sion will also focus on what further work would need to
be done to increase the value of the studies.
WPE9
BEGIN WITH THE END IN MIND: ISSUES IN 
PLANNING PHARMACOECONOMIC RESEARCH 
FOR MORE EFFECTIVE COMMUNICATION
Rindress D, Goetghebeur M, Welner S, McTavish A
BioMedCom Consultants inc, Montréal, Québec, Canada
WORKSHOP OBJECTIVE: This workshop has three ob-
jectives: 1) to illustrate the importance of early planning
of communication strategy for pharmacoeconomic re-
search; 2) to explore audience analysis as a tool in phar-
macoeconomic research planning; and 3) to examine the
persuasive impact of various types of communication on
decision-makers.
PARTICIPANTS WHO WOULD BENEFIT: Any re-
searcher in health outcomes and health economics with an
interest in augmenting the acceptability of their research to
and its persuasive impact on their target audience(s).
While considerable thought and resources are routinely
invested in the planning and conduct of pharmacoeco-
nomic research, the communication of research results is
often only considered long after the data has been com-
piled and analyzed. The purpose of this workshop is to
discuss how early planning of communication strategies,
including analysis of the target audience, may increase the
acceptability and usability of the research itself. Practical
experience in pharmacoeconomic communication and tra-
ditional communication and decision-making (not model-
ing) concepts are combined to stimulate new approaches
to effective practical research communication. A few inter-
active exercises will be included to illustrate the concepts
discussed. Participants should leave with greater aware-
ness of the issues surrounding communication planning
and some practical strategies for increasing the usefulness
of their work to end-users.
WTG1
APPLES AND APPLES, APPLES AND ORANGES: 
THE USE AND ABUSE OF AVERAGE DAILY DOSE 
IN PHARMACOECONOMIC RESEARCH
Loosbrock D1, Gibson J1, Dulisse B1,2, Edgell E3, Kody M3
1Health Outcomes Evaluation Group, Eli Lilly and Company, 
Indianapolis, IN, USA; 2Statistical and Mathematical Sciences, Eli 
Lilly and Company, Indianapolis, IN, USA; 3Global Health 
Outcomes Research, Eli Lilly and Company, Indianapolis, IN, USA
WORKSHOP OBJECTIVE: The purpose of this work-
shop is to develop skills to critically assess pharmacoeco-
nomic studies which compare daily dose or drug costs, by
considering the impact of differential population charac-
teristics, and by evaluating statistical methods often used
to address the differences.
PARTICIPANTS WHO WOULD BENEFIT: Developers
of treatment guidelines, medical directors, and formulary
decision-makers.
Pharmacoeconomic research often uses an average daily
dose to summarize drug costs. However, different antipsy-
chotic drugs differ significantly in their relative use for dif-
ferent diagnoses, age groups, or disease severity, which has
a marked affect on their average daily dose. It is mislead-
ing to compare average doses and consequent cost when
the compared populations have different distributions of
diagnosis, severity, or age, yet many non-randomized
pharmacoeconomic studies do not adequately control for
these factors. This workshop will prepare the audience to
assess such pharmacoeconomic studies more carefully,
both by clarifying the impact of differential population
characteristics, and by evaluating statistical methods often
used to address the differences. Physician survey data,
claims data, and observational study data will be used to
